ICAM1 and infection: TNFα pre‐treatment of HMVEC‐L did not lead to further increase in nucleocapsid protein‐positive cells compared to untreated HMVEC‐L after infection with 2 × 106 PFUs of SARS‐CoV‐2 (Figure 5h and i), despite increased ICAM‐1 intensity levels demonstrating TNFα‐driven HMVEC‐L cell activation (Figure 5j).